The FDA extends its review of Biogen Idec's (BIIB -2.8%) multiple-sclerosis pill BG-12 by three...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

The FDA extends its review of Biogen Idec's (BIIB -2.8%) multiple-sclerosis pill BG-12 by three months, although the agency hasn't requested additional studies. Last week, Biogen said that new data provided more evidence of the the drug's effectiveness in patients with relapsing-remitting MS.